Good week for access to affordable medicines

Despite concrete steps forward, the ENVI vote on clinical trials regulation falls short on transparency

Bracing for another delay – open innovation at the WHO?


EU Policy Opportunities in Biomedical Innovation and the Public Good

Statement on Medicines Patent Pool

Public Event on EU-MERCOSUR in Buenos Aires

Study provides recommendations on European Medicines Agency's communication on medicines

The Diagnosis of Childhood Bipolar Disease has led to Catastrophic Consequences

DG Trade State of Play reveals EU's ambitions for IP protection in FTAs

TRIPS-Plus IP demands from EU could halt South American trade deal

EU Mercosur Trade Negotiations in July

HAI Europe’s participation at the “Ad hoc meeting – Bilateral trade negotiations: State of Play”

Conflicts of interest at the European Medicines Agency (EMA) and the need for a review of staff regulations

Submission to the Consultative Expert Working Group (CEWG) on alternative financing

HAI Europe injects public health perspective into European Research and Innovation Framework

Statement on conflicts of interest delivered at WHA on behalf of HAI, Berne Declaration, KEI, TWN, PHM, IBFAN

Conflicts of Interest and the Future of Financing for WHO.

DG Trade public hearing on the “Protection and enforcement of IPR in third countries

EU-Mercosur Trade Negotiations: What Fate for Access to medicines?

Foundations: Conlicts of interests and Democracy issues

European drug regulator challenged over revolving door case involving former Director

Corporate funding linked to EU patient & consumer groups policy


Apply now: HAI Europe recruits two interns for 2011

EMA reviews transparency criteria

HAI research on financial disclosure featured in article: European politicians' call for greater transparency

Invitation: Meeting to discuss Global Health Education (GHE) and the People's Health Movement (PHM) in Europe

ACTA, Democracy & Access to Medicines

Selling Sickness through unbranded disease awareness campaigns?

HAI Europe Statement: EMA talks the ‘conflicts of interest’ talk, but will it walk the walk?

Report: Public information as a medicines marketing tool